Bildkälla: Stockfoto

Ascelia secures green light from the FDA to advance Oncoral into phase 2 - Redeye

This is good news for Ascelia as it opens up for a multicentre study in Europe and the US during 2022. Daily oral Oncoral will be tested in combination with LONSURF which is a premium approved product supplied by Ascelias partner Taiho Oncology. A daily combination has the potential to improve both efficacy, reduce negative side effects as well as reduce the pressure on specialist oncology care related to patients with metastatic gastric cancer. .

This is good news for Ascelia as it opens up for a multicentre study in Europe and the US during 2022. Daily oral Oncoral will be tested in combination with LONSURF which is a premium approved product supplied by Ascelias partner Taiho Oncology. A daily combination has the potential to improve both efficacy, reduce negative side effects as well as reduce the pressure on specialist oncology care related to patients with metastatic gastric cancer. .
Börsvärldens nyhetsbrev
ANNONSER